Dolomite Bio has launched the Nadia single cell platform, offering the fast-growing single cell research sector a solution for a range of applications.
Direct to consumer testing can potentially be quite dangerous without appropriate regulations and support to fully understand the implications of the information a consumer receives.
A more accurate test for Down’s Syndrome, Edwards and Patau syndromes has been developed by doctors, which could simplify screening processes.
The biotech industry is finally beginning to come around to the idea of Artificial Intelligence, in turn creating a demand for high paying jobs.
The Food and Drug Administration (FDA) approved Genentech’s Zelboraf as a treatment for patients diagnosed with a specific mutation of that disease.
ACMG is developing a series of one-page documents to help guide doctors through discussing incidental findings and NIPT results with patients
Scientists are discovering additional components of the DNA alphabet in animals. Does this have a special meaning, or are cellular machines making mistakes?
CBSN has reported on the successes of the NIH’s BabySeq Project and some of the privacy and discrimination concerns parents have voiced about sequencing their children
5 things to know: ensuring that payers, patients and providers are getting the most out of these exciting technologies and the care they can inform.
Genomic Vision has granted AmCare Genomics Laboratory exclusive rights to market their FSHD diagnostic assay in China
Genetic Testing Labs: Seize the Moment!
The analysis of more than 1,000 mouse models of cancer has challenged their ability to predict patient’ response to therapy.
Spark Therapeutic’s Luxturna, a gene therapy for a rare, genetic form of blindness, will be reviewed by a U.S. Food and Drug Administration panel this week.
Scientists have engineered a new way to deliver CRISPR technology inside cells by repairing the mutation that causes Duchenne muscular dystrophy.